Often, pharmaceutical companies avoid new laboratory testing methodologies preferring to stick to established procedures for drug development so as to avoid any potential regulatory ambiguity. This tendency to avoid new methodologies and regulatory scrutiny sometimes leads to slower progress, higher costs and lower probability of new product approvals. Furthermore, some pharmaceutical firms severely restrict academic research-based modifications to established laboratory testing procedures in drug development because of their concern over triggering costly adjustments to the established regulatory framework.
ENROUTE IMPORTS INC. - WELCOME TO ENROUTE IMPORTS INC.Enroute Imports Inc is actively involved in both the retail and food service sectors of the food industry under the trademarks VOIL and PRANZO. Co-packing of private label oils for national distributors and chain stores is a growing segment of Enroute's business. Its main market is Southern Ontario, but serves customers across Canada and exports around the world through a network of brokers.
Viventia is developing and advancing the next generation of human antibody-based therapeutics for use in oncology. Our approach combines the specificity of an antibody with the potency of a cytotoxic payload to provide targeted therapies for the safer and more efficacious treatment of cancer patients. Viventia has developed a potent payload, deBouganin, that when coupled to a targeting antibody can effectively kill cancer cells without harming normal cells. This differential targeting enhances the therapeutic potential of our drugs and provides prolonged clinical benefit. The versatile deBouganin payload has been chemically conjugated to full length antibodies as well as fused to numerous antibody fragments and has been found to be safe and efficacious in the clinic.